Article and Video CATEGORIES
Dr. Marco Ruiz is a Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, myelodysplastic syndrome, myelofibrosis, HIV related malignancies, stem cell transplants, geriatric oncology, and palliative medicine at the Miami Cancer Institute in Miami, Florida. He is also an experienced bone marrow transplant specialist and is active in cancer research. Growing up the son of a nurse, Dr. Ruiz knew at a young age that he wanted to pursue a career in medicine. But it was his father’s battle with cancer that sparked a passion for helping patients with the disease.
GRACE sat down with Dr. Marco Ruiz to discuss information regarding inhibitory molecules like the programmed cell death protein 1 (PD1) and its ligand (PDL1), and if they are active in lymphoma and in chronic lymphocytic leukemia (¿Están activos moléculas inhibitorias como el de la muerte programada 1 (PD1) y el ligando de muerte programada 1 (PDL1) en el linfoma y en la leucemia linfocítica crónica (LLC)?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and Chronic Lymphocytic Leukemia & Non-Hodgkin Lymphoma, (Leucemia crónica linfocítica y linfoma no Hodgkin).
We would like to thank the following company for their support of this program:
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…